Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells $105,420.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $105,420.00. Following the transaction, the chief operating officer now directly owns 262,660 shares of the company’s stock, valued at $9,889,149. This represents a 1.05 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, April 23rd, Patrick John Finn sold 2,058 shares of Twist Bioscience stock. The stock was sold at an average price of $39.99, for a total value of $82,299.42.
• On Wednesday, April 2nd, Patrick John Finn sold 206 shares of Twist Bioscience stock. The shares were sold at an average price of $38.73, for a total value of $7,978.38.

Twist Bioscience Trading Down 5.5 %

Shares of NASDAQ:TWST opened at $30.82 on Friday. The stock’s 50-day simple moving average is $38.63 and its two-hundred day simple moving average is $43.65. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -9.12 and a beta of 2.54. Twist Bioscience Co. has a 52-week low of $30.72 and a 52-week high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on TWST shares. JPMorgan Chase & Co. lowered their price target on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Tuesday. Guggenheim reaffirmed a “buy” rating and issued a $50.00 target price on shares of Twist Bioscience in a report on Tuesday. Robert W. Baird cut their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a report on Tuesday. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, Barclays cut their target price on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $50.40.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors have recently bought and sold shares of the stock. Versant Capital Management Inc raised its stake in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock worth $27,000 after buying an additional 580 shares during the period. GAMMA Investing LLC raised its stake in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after acquiring an additional 303 shares during the period. Van ECK Associates Corp lifted its holdings in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience in the third quarter worth approximately $34,000. Finally, Banque Transatlantique SA purchased a new stake in shares of Twist Bioscience in the fourth quarter worth $43,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.